Biotech IV Monitor

BPMC — Blueprint Medicines Corporation

Acquired by Sanofi · July 2025
Blueprint Medicines Corporation was acquired by Sanofi in July 2025. BPMC no longer trades, so its trials are no longer stock catalysts and are left off the trial calendar. The records below are kept for reference; the programs now belong to Sanofi, and their dates may not have been updated since.

Clinical trial readout dates for Blueprint Medicines Corporation, compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is December 2026.

Next readoutDecember 2026in ~1 month
Upcoming readouts41 Phase 3

Upcoming readouts

Phase 2 BLU-808
Chronic Inducible Urticaria; Chronic Spontaneous Urticaria · NCT06931405
December 2026
Ongoing
Phase 2 Avapritinib
Indolent Systemic Mastocytosis · NCT03731260
June 2027
Ongoing
Phase 1/2 BLU-924
Advanced Solid Tumor; Non-Small Cell Lung Cancer · NCT07629960
September 2029
Recruiting
Phase 2/3 Elenestinib
Indolent Systemic Mastocytosis; Smoldering Systemic Mastocytosis · NCT04910685
September 2032
Recruiting

Companies working on similar indications

Discussion

No messages yet. If you follow BPMC, you can start the conversation.
Contact — questions or corrections about BPMC: dukeupt@gmail.com